

The Manager
Company Announcements Office
ASX Limited

APAS® INCLUDED ON THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS AS AN IN VITRO DIAGNOSTIC DEVICE.

Adelaide, Australia, 28 March 2017: LBT Innovations (LBT) as the Australian representative and Joint Venture partner in Clever Culture Systems AG (CCS), has received confirmation that the Automated Plate Assessment System (APAS®) has been included on the Australian Register of Therapeutic Goods (ARTG). Following an application to the Therapeutic Goods Administration (TGA), the device has been included on the ARTG as an In Vitro Diagnostic Device under registration number ARTG 287170.

Inclusion on the ARTG is a legal requirement for the supply of any medical device in Australia and is an important milestone to support the sale and distribution of APAS® products by CCS within Australia.

LBT CEO and Managing Director Brent Barnes, says “The inclusion by the TGA of the APAS® technology is part of the global distribution strategy for CCS in preparation of bringing product to market. This milestone follows FDA clearance for the technology in October 2016 based on an extensive independent 10,000 patient clinical study across two continents and supported by peer review publications in leading journals such as the American Society of Microbiology’s prestigious Journal of Clinical Microbiology.”

APAS® is a breakthrough artificial intelligence technology and a global first for the automated imaging, image analysis, interpretation and reporting of growth on microbiology culture plates after incubation. APAS® enables the faster diagnosis and reporting of infection and disease. The technology is at least three times more efficient than manual plate reading and meets the market need for helping with increased workloads, quality demands and decreasing budgets.

The TGA registration will cover all models of APAS® technology.

– ENDS –

About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (APAS®). Based on LBT’s intelligent imaging and interpretative software, US FDA-cleared APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (CCS) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT’s third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

CONTACTS

| LBT Innovations | Media Relations |
|---|--|
| Brent Barnes Chief Executive Officer & Managing Director Tel: +61 (0)8 8227 1555 E: info@lbtinnovations.com | Sarah Kemter Monsoon Communications Tel: +61 (0)3 9620 3333 M: +61 (0) 407 162 530 E: sarahk@monsoon.com.au |